ATE259223T1 - Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung - Google Patents

Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Info

Publication number
ATE259223T1
ATE259223T1 AT00951577T AT00951577T ATE259223T1 AT E259223 T1 ATE259223 T1 AT E259223T1 AT 00951577 T AT00951577 T AT 00951577T AT 00951577 T AT00951577 T AT 00951577T AT E259223 T1 ATE259223 T1 AT E259223T1
Authority
AT
Austria
Prior art keywords
composition containing
donor
pharmaceutical composition
therapeutic use
patient
Prior art date
Application number
AT00951577T
Other languages
English (en)
Inventor
Maurice Israel
La Porte Sabine De
Philippe Fossier
Emmanuel Chaubourt
Gerard Baux
Christiane Leprince
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE259223T1 publication Critical patent/ATE259223T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00951577T 1999-06-11 2000-06-09 Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung ATE259223T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907442A FR2794647A1 (fr) 1999-06-11 1999-06-11 Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
PCT/FR2000/001612 WO2000076451A2 (fr) 1999-06-11 2000-06-09 Composition pharmaceutique comprenant du no un compose donneur de no, ou inducteur de la formation de no et son utilisation en therapie

Publications (1)

Publication Number Publication Date
ATE259223T1 true ATE259223T1 (de) 2004-02-15

Family

ID=9546698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00951577T ATE259223T1 (de) 1999-06-11 2000-06-09 Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Country Status (12)

Country Link
US (1) US6872751B2 (de)
EP (1) EP1231908B1 (de)
JP (1) JP2003506320A (de)
AT (1) ATE259223T1 (de)
AU (1) AU776692B2 (de)
CA (1) CA2376302A1 (de)
DE (1) DE60008293T2 (de)
DK (1) DK1231908T3 (de)
ES (1) ES2213032T3 (de)
FR (1) FR2794647A1 (de)
PT (1) PT1231908E (de)
WO (1) WO2000076451A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
JP4723476B2 (ja) * 2003-02-14 2011-07-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
WO2007020917A1 (ja) * 2005-08-18 2007-02-22 The University Of Tokushima ユートロフィン産生の増強持続剤とこれを用いる加工食品
EP2786749A1 (de) * 2006-02-03 2014-10-08 Nicox S.A. Verwendung eines Nitrooxyderivats eines Heilmittels zur Behandlung muskulärer Dystrophien
US9452117B2 (en) * 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
EP2837390A1 (de) * 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Kombiniertes pharmazeutisches Paräparat zur Verwendung bei der Behandlung von Nerven-Muskel-Störungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE192922T1 (de) * 1993-11-02 2000-06-15 Us Health Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
AU2208097A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
DE29709820U1 (de) * 1996-06-10 1997-07-31 NUTREND, s.r.o., Olomouc Lebensmittel-Spezialzusatz
EP2292630B1 (de) * 1996-09-27 2015-11-25 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services O2-substituierte 1-(2-carboxylato)pyrrolidin-1-yl Diazen-1-ium-1,2-Diolate
NO310618B1 (no) * 1997-04-10 2001-07-30 Ono Pharmaceutical Co Kondenserte piperidinforbindelser, fremstilling og anvendelse derav, samt preparater omfattende slike forbindelser
JP4856295B2 (ja) * 1997-07-03 2012-01-18 アメリカ合衆国政府 新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物
WO2000053191A2 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Modulation of skeletal muscle precursor cell activation
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Also Published As

Publication number Publication date
AU776692B2 (en) 2004-09-16
EP1231908B1 (de) 2004-02-11
DE60008293T2 (de) 2005-01-13
FR2794647A1 (fr) 2000-12-15
US6872751B2 (en) 2005-03-29
ES2213032T3 (es) 2004-08-16
US20020164383A1 (en) 2002-11-07
JP2003506320A (ja) 2003-02-18
EP1231908A2 (de) 2002-08-21
AU6447300A (en) 2001-01-02
PT1231908E (pt) 2004-06-30
WO2000076451A2 (fr) 2000-12-21
CA2376302A1 (fr) 2000-12-21
WO2000076451A3 (fr) 2002-06-20
DE60008293D1 (de) 2004-03-18
DK1231908T3 (da) 2004-06-14

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE259223T1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
AU4258601A (en) Divided dose therapies with vascular damaging activity
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
UA23763A (uk) Спосіб одержаhhя лікувальhого засобу при захворюваhhях, що супроводжуються порушеhhям фуhкцій цеhтральhої hервової системи
GB9917290D0 (en) Pharmaceutical composition
EP0880967A3 (de) Nephroprotektive Arzneimittel
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
GR1003199B (el) Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
UA31379A (uk) Спосіб лікування ішемічної хвороби серця
RU2001125147A (ru) Способ лечения заболеваний пародонта

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1231908

Country of ref document: EP

REN Ceased due to non-payment of the annual fee